Cancer immunotherapies are designed to work in conjunction with a patient's immune system to increase native anti-tumor responses. Charles River’s well-established syngeneic mouse portfolio provides an effective approach for studying how cancer therapies perform in the presence of a functional immune system.
This webinar reviews the new whole-exome sequencing results of our models in conjunction with our previously reported characterization data to known immune checkpoint inhibitors (e.g., anti-PDL-1, anti-PD-1, anti-CTLA-4) as well as baseline tumor infiltrate flow data. This combination enhances our ability to help you choose the best models to predict sensitivity to targeted therapies.
- Cordula Tschuch, PhD, Senior Research Scientist, Charles River